Here's a view inside drug partnering, with the main point being that Big Pharma is much more open to collaboration. That isn't news to most, but still good personal insights in the article. I'm surprised, though at one of the stats in the article: 33% of all Big Pharma leads are in-licensed. Put another way, 2/3rds of all Big Pharma programs are still internally sourced. That doesn't seem right - internal discovery in Big Pharma seems to me to have shrunken to a minority activity - maybe 25% of all big Pharma R&D. What's your impression?